| Today’s Big NewsMar 20, 2025 |
|
Leverage industry-leading capabilities powered by Kinetic™ to streamline and optimize commercialization activities. Let Syneos Health help increase your probability of market success.
|
|
| By James Waldron Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. |
|
|
|
By James Waldron The CD20-directed antibody, dubbed DR-0201, is a bispecific myeloid cell engager that Dren has been testing in a phase 1 trial for B-cell non-Hodgkin lymphoma. |
By James Waldron Elevation is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the antibody-drug conjugate company to lay off 70% of its staff. |
Sponsored by Syneos Health Dr. Steven O'Day of Agenus discusses the future of cancer immunotherapy on The Top Line podcast. Learn about 'cold' tumors and a potential '2.0 revolution' in immuno-oncology. |
By Gabrielle Masson Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to turn its focus toward autoimmune diseases. |
By Nick Paul Taylor Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. Biomarker-positive patients were rarer than expected in some tumor types, prompting the biotech to focus MRT-2359 development on prostate cancer while continuing to advance its alliance with Novartis toward phase 2. |
By Nick Paul Taylor BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to co-develop the prospect, BioNTech let the option expire as part of its portfolio prioritization. |
By Gabrielle Masson Cell programming biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of therapeutics development. |
By Darren Incorvaia For the 80 million people worldwide who have celiac disease, the only treatment available is to cut grains like pasta and bread out of their lives. But researchers are hoping to change that with a new cell therapy that, in mice, was able to tamp down the immune system’s overreaction to gluten. |
By Darren Incorvaia As fungi resistant to traditional treatments continue to spread around the globe, researchers from China Pharmaceutical University in Nanjing have identified a bacterial compound that can kill infectious fungi even if they’re resistant to other antifungals. |
By Kevin Dunleavy Two months after U.S. President Donald Trump proclaimed DEI programs “illegal and immoral,” Roche has reportedly scrapped its high-profile five-year plan to increase the diversity of its leadership. Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, according to Reuters. |
Fierce podcastsDon’t miss an episode |
| | Executive Editor Heather Landi and Senior Writer Paige Minemyer sit down to chat about the evolution of the Fierce 15 project and honorees. |
|
|---|
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
